Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (61-70 of 168) with videos related to

Pageof 17
Sort By:
Lung Cancer (Amsterdam, Netherlands)|August 12, 2008
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancerTim Eisen, Nick Thatcher, Serge Leyvraz, et al.
STAR Protocols|July 14, 2021
Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouseSai Sakktee Krisna, Christophe Goncalves, Natascha Gagnon, et al.
Molecular Cancer Research : MCR|October 24, 2003
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosisKoren K Mann, Ada Rephaeli, April L Colosimo, et al.
The Journal of Clinical Investigation|September 27, 2005
Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylationKoren K Mann, Alessandra M S Padovani, Qi Guo, et al.
Cancer Research|July 19, 2002
Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell linesYoung-Ah Suh, Ho-Young Lee, Arvind Virmani, et al.
Oncotarget|April 19, 2017
Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cellsChia-Hao Chang, Krikor Bijian, Dinghong Qiu, et al.
Blood|October 7, 2004
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell linesZuanel Diaz, Myrian Colombo, Koren K Mann, et al.
Investigational New Drugs|November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumorsAlbiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Trends in Cancer|May 20, 2026
Mouse models of immune-related adverse events: progress, challenges, and opportunitiesTheodoros Papadopoulos, Ariel Pinto, Madelyn J Abraham, et al.
Oncogene|August 20, 2004
Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promotersCatia Morelli, Cecilia Garofalo, Diego Sisci, et al.
Pageof 17

Showing results (61-70 of 168) with videos related to

Sort By:
Pageof 17
Lung Cancer (Amsterdam, Netherlands)|August 12, 2008
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancerTim Eisen, Nick Thatcher, Serge Leyvraz, et al.
STAR Protocols|July 14, 2021
Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouseSai Sakktee Krisna, Christophe Goncalves, Natascha Gagnon, et al.
Molecular Cancer Research : MCR|October 24, 2003
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosisKoren K Mann, Ada Rephaeli, April L Colosimo, et al.
The Journal of Clinical Investigation|September 27, 2005
Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylationKoren K Mann, Alessandra M S Padovani, Qi Guo, et al.
Cancer Research|July 19, 2002
Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell linesYoung-Ah Suh, Ho-Young Lee, Arvind Virmani, et al.
Oncotarget|April 19, 2017
Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cellsChia-Hao Chang, Krikor Bijian, Dinghong Qiu, et al.
Blood|October 7, 2004
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell linesZuanel Diaz, Myrian Colombo, Koren K Mann, et al.
Investigational New Drugs|November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumorsAlbiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Trends in Cancer|May 20, 2026
Mouse models of immune-related adverse events: progress, challenges, and opportunitiesTheodoros Papadopoulos, Ariel Pinto, Madelyn J Abraham, et al.
Oncogene|August 20, 2004
Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promotersCatia Morelli, Cecilia Garofalo, Diego Sisci, et al.
Pageof 17